OncoCyte’s New Sales Agreement and Termination of Old Deal

OncoCyte (OCX) has shared an update.

Oncocyte Corporation has initiated a sales agreement with Needham & Company, LLC to potentially sell up to $7.5 million of its common stock at market prices. This sales option will be conducted through “at the market offerings,” with Needham & Company acting as the sales agent. While there is no obligation to sell these shares, proceeds will be used for corporate purposes such as working capital. Additionally, a previous agreement with BTIG, LLC has been terminated, concluding their prior arrangement for a $50 million sales program.

For detailed information about OCX stock, go to TipRanks’ Stock Analysis page.